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Abstract
Purpose: To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and
their outcomes in early-phase trials using pathway-targeting agents.
Patients and Methods: We analyzed characteristics of 238 patients with mCRC referred to the phase 1 trials unit at MD
Anderson Cancer Center. KRAS, PIK3CA and BRAF status were tested using PCR-based DNA sequencing.
Results: Fifty-one percent of patients harbored KRAS mutations; 15% had PIK3CA mutations. In the multivariate regression
model for clinical characteristics KRAS mutations were associated with an increased incidence of lung and bone metastases
and decreased incidence of adrenal metastases; PIK3CA mutations were marginally correlated with mucinous tumors
(p = 0.05). In the univariate analysis, KRAS and PIK3CA mutations were strongly associated. Advanced Duke’s stage
(p,0.0001) and KRAS mutations (p = 0.01) were the only significant independent predictors of poor survival (Cox
proportional hazards model). Patients with PIK3CA mutations had a trend toward shorter progression-free survival when
treated with anti-EGFR therapies (p = 0.07). Eighteen of 78 assessable patients (23%) treated with PI3K/Akt/mTOR axis
inhibitors achieved stable disease [SD] $6 months or complete response/partial response (CR/PR), only one of whom were
in the subgroup (N = 15) with PIK3CA mutations, perhaps because 10 of these 15 patients (67%) had coexisting KRAS
mutations. No SD$6 months/CR/PR was observed in the 10 patients treated with mitogen-activating protein kinase (MAPK)
pathway targeting drugs.
Conclusions: KRAS and PIK3CA mutations frequently coexist in patients with colorectal cancer, and are associated with
clinical characteristics and outcome. Overcoming resistance may require targeting both pathways.
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Introduction
There is increasing support for the concept that specific
mutations predict the clinical manifestations and response to
therapy of patients with cancer. In colorectal cancer, RAS
mutations have received mounting scrutiny. In particular,
activating mutations in KRAS drive resistance to anti-EGFR
therapies in patients with metastatic disease. [1,2] However,
a subset of individuals with KRAS mutations (p.G13D) might
derive benefit from anti-EGFR therapies. [3] The role of PIK3CA
mutations in predicting resistance to anti-EGFR therapies has
been debated, with initial studies reaching opposing conclusions.
[4,5] Recently, a multicenter retrospective study showed that
PIK3CA mutations in exon 20 were involved in resistance to anti-
EGFR therapies, whereas mutations in exon 9 were not. [6]
Finally, our group demonstrated that activating mutations in
PIK3CA may predict response to PI3K/Akt/mTOR inhibitors. [7]
Here, we review the clinical and molecular characteristics of
patients with metastatic colorectal cancer (mCRC) who were
referred to our clinical trials unit. The purpose of the study was to
identify clinical characteristics associated with KRAS and PIK3CA
mutations, and outcomes on early clinical trials of PI3K/Akt/
mTOR and MAPK inhibitors.
Results
Patient Characteristics
Patient and tumor clinicopathologic characteristics for the 238
study patients are listed in Table 1. Fifty-four percent of patients
were men. Seventy-one percent of patients were over the age of
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fifty. Most patients (69%) were Caucasians. The most common
sites of metastases were liver, lymph nodes and lung, found in
83%, 75%, and 72% of patients, respectively. All 238 patients
were tested for KRAS status. One-hundred-and-twenty-two
patients (51%) had KRAS mutations. Of the 168 patients tested
for PIK3CA mutations, 25 (15%) had a mutation. Of the 173
patients tested for BRAF mutations, 11 (6%) had a mutation.
Frequency of KRAS Mutation Subtypes
Next, we assessed the incidence of different types of KRAS
mutations. The location of KRAS mutations was available in 108
out of 122 patients. The most frequent KRAS mutation was
p.G12D (31 patients [29%]), followed by p.G12V (23 patients
[21%]), p.G12A (14 patients [13%]) and p.G13D (13 patients
[12%]). Other mutations occurred at the following low incidences:
p.G12C (11 patients [10%]), p.G12S (8 patients [7%]), p.Q61H (5
patients [5%]) and p.G12R, p.G13C and p.G12F, one patient
each (1%).
Evaluation of ‘‘KRASness’’
Clinical Characteristics. Patients with KRAS mutations
(N= 122) had a higher incidence of lung (79% [96/122] vs.
66% [76/116], p= 0.03) and bone metastases (20% [24/122] vs.
9% [11/116], p = 0.03) compared to those with wild-type KRAS
(N= 116).
To further assess the association between KRAS mutations and
different clinical features in patients with colorectal cancer, we
fitted univariate and multivariate logistic regression models. The
univariate models suggested that patients with KRAS mutations
had a higher probability of having lung (p= 0.02) and bone
metastases (p = 0.03) (Table 2). We fitted a multivariate model
including those variables with univariate p-values ,0.5 in the full
model. After backward model selection, the multivariate model
showed that increased lung and bone metastases and decreased
adrenal metastases are significantly associated with KRAS muta-
tions (Table 2)
Molecular Characteristics. One-hundred-and-sixty-eight
patients had testing for both KRAS and PIK3CA mutations. One-
half of the patients tested (N=84) had a KRAS mutation and one-
half (N= 84) did not. Compared to KRAS wild-type patients,
patients harboring KRAS mutations more frequently had PIK3CA
mutations (21% [18/84] vs. 8% [7/84], p = 0.03). As previously
reported, BRAF and KRAS mutations were mutually exclusive (173
patients tested for both) (Table 1). [6]
PIK3CA mutations were significantly associated with KRAS
mutations in univariate models (p = 0.03). Of interest, when we
introduced molecular features into the clinical multivariate model
(i.e., PIK3CA status), the only variable associated with KRAS
mutations was PIK3CA (data not shown).
KRAS Mutations Were Associated With a Shorter OS
We conducted a univariate analysis of survival for different
patient characteristics, including age, gender, race, tumor type
(mucinous vs. not), Duke’s stage at diagnosis, site of primary
tumor, KRAS, BRAF and PIK3CA mutations. In the multivariate
analysis, Duke’s stage at diagnosis and KRAS status were significant
predictors of survival (KRAS HR 1.71, 95% CI 1.11–2.62)
(Table 3). The median OS from time of diagnosis for patients
with KRAS mutations was 57.5 months (95% CI: 50.0–64.8
months), whereas for KRAS wild-type patients, the median OS was
89.5 months (95% CI 63.5–120.1 months) (log-rank p= 0.007)
(Figure 1).
We also assessed whether different types of KRAS mutations
were associated with survival. We found no differences in OS
across different types of KRAS mutations. For example, the median
OS for patients with a codon 12 mutation was 57.5 months (95%
CI 50–62.2 months) and the median OS for patients with a codon
13 mutation was 56.8 months (95% CI 28.8- not estimable) (log-
rank p-value = 0.52). We further assessed OS, as defined by the
specific type of amino acid involved in the different mutations. For
this analysis we kept only subgroups with at least 10 observations
(Table S1). There was no difference in OS. However, the number
of patients in each subtype group was small, ranging from 11 to
31, precluding definitive conclusions.
Evaluation of ‘‘PIK3CAness’’
Clinical Features. To assess the association between PIK3CA
mutations and different clinical features in patients with colorectal
cancer, we tried to fit univariate and multiple logistic regression
models. The univariate model suggested that patients with PIK3CA
mutations more frequently had mucinous tumors (p = 0.04). They
also had a trend to have less frequent liver metastases compared to
patients with PIK3CA wild-type tumors (OR 0.40, p = 0.07)
(Table 4). In the multivariate analysis, mucinous tumors were
marginally significant (p-value = 0.05), with patients having
mucinous tumors more frequently having PIK3CA mutations
(OR 2.61; 95% CI 0.99–6.87). In addition, age showed a week
trend (p-value = 0.15), with older patients less frequently having
PIK3CA mutations (OR 0.52; 95% CI 0.22–1.26). As mentioned
previously, PIK3CA status was not an independent variable
predicting survival in multivariate analysis.
Molecular Characteristics. 168 (71%) patients were tested
for PIK3CA mutations. Of the 143 patients with wild-type PIK3CA,
66 (46%) had KRAS mutations. Of the 25 (15%) patients with
PIK3CA mutations, 18 (72%) had KRAS mutations (p = 0.03)
(Table 1). Of the 147 patients tested for both PIK3CA and BRAF,
one patient (0.7%) had both mutations. A recent report showed
that PIK3CA mutations in exon 20 were involved in resistance to
anti-EGFR therapies, whereas mutations in exon 9 were not. [6]
Further, although KRAS mutations are believed to predict
resistance to EGFR inhibitor treatment, a subset of individuals
with KRAS p.G13D mutations may still derive benefit from anti-
EGFR therapies. [3] We, therefore, analyzed coexistent PIK3CA
mutations (exon 9 and 20) in patients with KRAS mutations. We
found that patients with KRAS p.G13D mutations had the lowest
incidence of PIK3CA mutations (10%) compared to patients with
KRAS p.G12A (36% had PI3KCA mutations), p.G12C (33%),
p.G12D (22%) and p.G12V (12%). Moreover, none of the nine
patients with KRAS p.G13D mutations had a PIK3CA mutation in
exon 20, whereas PIK3CA mutations in exon 20 were found in all
other types of KRAS mutations (Table S2). However, the small
numbers of patients precludes drawing any statistically significant
conclusions.
PFS on anti-EGFR treatment. We analyzed PFS in patients
treated with anti-EGFR therapies (cetuximab or panitumumab).
Patients with KRAS mutant mCRC treated with anti-EGFR
therapies (N= 24) had shorter PFS compared to patients with
wild-type KRAS (N= 98) (15 vs. 22 weeks, p= 0.01). Within the
group of patients tested for PIK3CA mutations who received anti-
EGFR therapies, patients with PIK3CA mutations (N=9) had
a trend toward a shorter PFS than PIK3CA wild-type patients
(N= 82) (17 vs. 22 weeks, p = 0.07) (Figure S1).
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Table 1. Patient characteristics.
VARIABLES Overall, N =238 KRAS wild-type N=116 KRAS mutation N=122 p-value
Gender
Male 128 (54%) 63 (54.3%) 65 (53.3%) 0.90
Female 110 (46%) 53 (45.7%) 57 (46.7%)
Age (years)
#50 68 (29%) 33 (28.5%) 35 (28.7%) 0.94
.50 170 (71%) 83 (71.5%) 87 (71.3%)
Race
White 165 (69%) 82 (70.7%) 83 (68.0%) 0.25
Hispanic 21 (9%) 13 (11.2%) 8 (6.6%)
African-American 41 (17%) 15 (12.9%) 26 (21.3%)
Other 11 (5%) 6 (5.2%) 5 (4.1%)
Histology
Non-mucinous 197(17%) 99 (85.3%) 98 (80.3%) 0.39
Mucinous 41 (83%) 17 (14.7%) 24 (19.7%)
Siteˆ
Ascending 56 (24%) 21 (18.6%) 35 (28.9%) 0.28
Transverse 15 (6%) 7 (6.2%) 8 (6.6%)
Descending/sigmoid 95 (41%) 48 (42.5%) 47 (38.8%)
Rectum 68 (29%) 37 (32.7%) 31 (25.6%)
Dukes stage#
A 1 (0.4%) 0 (0%) 1 (0.8%) 0.51
B 19 (8%) 10 (8.8%) 9 (7.4%)
C 79 (33%) 42 (36.8%) 37 (30.3%)
D 137 (58%) 62 (54.4%) 75 (61.5%)
BRAF*
wild-type 162 (94%) 83 (88.3%) 79 (100%) 0.002
mutated 11 (6%) 11 (11.7%) 0 (0%)
PIK3CA**
wild-type 143 (85%) 77 (91.7%) 66 (78.6%) 0.03
mutated 25 (15%) 7 (8.3%) 18 (21.4%)
Adjuvant chemo
None 17 (7%) 7 (13.5%) 10 (20.8%) 0.43
Yes 83 (93%) 45 (86.5%) 38 (79.2%)
Anti-EGFR therapy
No 109 (46%) 15 (12.9%) 94 (77.0%) 0.0001
Yes 129 (54%) 101 (87.1%) 28 (23.0%)
Metastases
Liver 198 (83%) 94 (81.0%) 104 (85.2%) 0.39
Lung 172 (72%) 76 (65.5%) 96 (78.7%) 0.03
Adrenal gland 31 (13%) 19 (16.4%) 12 (9.8%) 0.18
Brain 9 (4%) 4 (3.4%) 5 (4.1%) 1.00
Peritoneum 81 (34%) 36 (31.0%) 45 (36.9%) 0.41
Lymph nodes 179 (75%) 85 (73.3%) 94 (77.0%) 0.55
Ovarian 14 (6%) 8 (6.9%) 6 (4.9%) 0.59
Bone 35 (15%) 11 (9.5%) 24 (19.7%) 0.03
Sˆite at diagnosis was unknown for four patients,
#Dukes stage at diagnosis was unknown for two patients,
*BRAF status was known in 173 patients,
**PIK3CA status was known in 168 patients
doi:10.1371/journal.pone.0038033.t001
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Table 2. Univariate and multivariate logistic regression model for clinical characteristics associated with KRAS mutations in
colorectal cancer.
Univariate regression model (N=238)
Variable Coefficient SE P-value Odds Ratio 95% Confidence Interval
Age at diagnose .50 (vs. #50) 20.01 0.29 0.97 0.99 0.56 1.74
Male (vs. female) 20.04 0.26 0.87 0.96 0.58 1.60
Mucinous (vs. non-mucinous) 0.35 0.35 0.31 1.42 0.72 2.82
Dukes = a, b, c (vs. d) 20.29 0.26 0.27 0.75 0.45 1.26
Liver metastases = yes (vs. no) 0.3 0.35 0.39 1.35 0.68 2.68
Lung metastases = yes (vs. no) 0.66 0.3 0.02 1.94 1.09 3.46
Adrenal = yes (vs. no) 20.59 0.39 0.14 0.56 0.26 1.21
Brain metastases = yes (vs. no) 0.18 0.68 0.79 1.20 0.31 4.57
Peritoneal metastases = yes (vs. no) 0.26 0.27 0.34 1.30 0.76 2.23
Lymph node metastases = yes (vs. no) 0.2 0.3 0.50 1.22 0.68 2.21
Ovarian metastases = yes (vs. no) 20.36 0.56 0.52 0.70 0.24 2.08
Bone metastases = yes (vs. no) 0.85 0.39 0.03 2.34 1.09 5.02
Multivariate Regression Model (N=238)
Intercept 20.40 0.25 0.12 - - -
Lung mets = yes (vs. no) 0.61 0.31 0.05 1.85 1.01 3.36
Bone mets = yes (vs. no) 0.83 0.41 0.05 2.29 1.02 5.14
Adrenal = yes (vs. no) 20.86 0.42 0.04 0.42 0.19 0.96
doi:10.1371/journal.pone.0038033.t002
Figure 1. Kaplan-Meier plot of overall survival (OS) and KRAS status. Patients with KRAS wild-type mCRC had longer OS compared to KRAS
mutant patients (tick marks represent patients still alive at time of last follow up).
doi:10.1371/journal.pone.0038033.g001
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Response to PI3K/Akt/mTOR Inhibitors or MAP Kinase
Pathway Inhibitors: impact of coexistence of PIK3CA and
KRAS mutations
Eighty patients were treated on phase 1 protocols containing
PI3K/Akt/mTOR inhibitors (NCT00454090, NCT00554268,
NCT00610493, NCT00687622, NCT00726583, NCT00731263,
NCT00756847, NCT00761644, NCT00770731, NCT00880321,
NCT00920257, NCT00940381, NCT00972686, NCT01054313,
NCT01072175, NCT01087554, NCT01087983, NCT01138085,
NCT01155453, NCT01263145) (www.clinicaltrials.gov). Seventy-
eight patients were assessable for response by RECIST (Figure 2).
Of these 78 patients, 43 had a KRAS mutation in their tumors and
35 were KRAS wild-type. Of the 43 patients with KRAS-mutant
disease, 9 (21%) attained SD $6 months/CR/PR; of the 33
patients with KRAS wild-type, 9 (27%) had SD $6 months/CR/
PR (Fisher’s exact test p= 0.59).
Fifteen patients with PIK3CA mutations were treated with
PI3K/Akt/mTOR inhibitors, and one (7%) had SD $6 months/
CR/PR; 10 of those patients (67%) had a concomitant KRAS
mutation and none had a BRAF mutation. Sixty-three patients
with wild-type or unknown PIK3CA status were treated with
PI3K/Akt/mTOR inhibitors, and 17 (27%) had SD $6 months/
CR/PR (Fisher’s exact test for SD$6 months/CR/PR in PIK3CA
mutant vs. wild-type p= 0.17); 33 of these patients (52%) had
a KRAS mutation.
A total of 10 patients were treated with MAPK pathway
inhibitors (generally BRAF or MEK inhibitors). Of those patients,
four had BRAF and five had KRAS mutations. None had PIK3CA
Table 3. Univariate Analysis and Multivariate Cox Model for Overall Survival.
Univariate Cox proportional hazards model for overall survival
Covariate HR 95% CI p-value N death N*
male (vs. female) 1.15 0.76–1.75 0.50 94 238
mucinous (vs. non-mucinous) 1.59 0.96–2.64 0.07 94 238
Dukes = a, b, c (vs. d) 0.38 0.25–0.60 ,0.0001 93 236
BRAF= yes (vs. no) 1.28 0.46–3.55 0.63 64 173
PIK3CA= yes (vs. no) 1.15 0.61–2.17 0.67 63 168
KRAS= yes (vs. no) 1.77 1.16–2.70 0.01 94 238
Multivariate Cox proportional hazards model for overall survival (n =236; death =93)
Dukes = a, b, c (vs. d) 0.39 0.25–0.60 ,0.0001
KRAS= yes (vs. no) 1.71 1.11–2.62 0.01
doi:10.1371/journal.pone.0038033.t003
Table 4. Univariate and multivariate logistic regression model for clinical characteristics associated with PIK3CA mutations in
colorectal cancer.
Univariate regression model (N=168)
variable Coefficient SE P-value Odds Ratio 95% Confidence Interval
Age at diagnose .50 (vs. #50) 20.70 0.44 0.11 0.49 0.21 1.18
male (vs. female) 0.54 0.46 0.24 1.72 0.70 4.25
mucinous (vs. non-mucinous) 1.01 0.49 0.04 2.75 1.05 7.14
Dukes = a, b, c (vs. d) 0.57 0.44 0.19 1.77 0.75 4.15
Liver metastases = yes (vs. no) 20.93 0.51 0.07 0.39 0.15 1.07
lung metastases = yes (vs. no) 20.19 0.47 0.68 0.83 0.33 2.06
Adrenal = yes (vs. no) 0.41 0.61 0.50 1.51 0.46 4.96
Brain metastases = yes (vs. no) 1.11 0.89 0.22 3.03 0.52 17.46
Peritoneal metastases = yes (vs. no) 0.47 0.44 0.28 1.60 0.68 3.81
LN metastases = yes (vs. no) 0.90 0.64 0.16 2.46 0.70 8.73
Ovarian metastases = yes (vs. no) 20.79 1.06 0.46 0.45 0.06 3.66
Bone metastases = yes (vs. no) 0.10 0.59 0.86 1.11 0.35 3.55
Multivariate regression model (N=168)
Intercept 21.54 0.38 ,.0001 - - -
mucinous (vs. non-mucinous) 0.96 0.49 0.05 2.61 0.99 6.87
Age at Dx .50 (vs. #50) 20.65 0.45 0.15 0.52 0.22 1.26
doi:10.1371/journal.pone.0038033.t004
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mutations. None of those patients had SD $6 months/CR/PR
(figure 2).
Discussion
In 238 patients with colorectal cancer referred to our clinical
trials unit, we found that 122(51%) had KRASmutations. The most
frequent KRAS mutation subtypes were p.G12D (31 patients
[25%]), followed by p.G12V (23 patients [19%]), p.G12A (14
patients [11%]) and p.G13D (13 patients [11%]). This incidence of
KRAS subtypes was consistent with that reported in the Catalogue
of Somatic Mutations in Cancer (COSMIC) database (www.
sanger.ac.uk/genetics/CGP/cosmic/accessed on June 17th, 2011).
In the multivariate analysis of clinical characteristics, KRAS
mutations were associated with increased incidence of lung and
bone metastases (p = 0.05 for each variable) and decreased
incidence of adrenal metastases (p = 0.04) compared to KRAS
wild-type patients. Previous studies found a higher probability of
lung metastases in patients with mCRC with KRAS mutations.
[8,9] At the molecular level, patients harboring KRAS mutations
more frequently had concomitant PIK3CA mutations compared to
individuals with wild-type KRAS (21% vs. 8%, [p= 0.03]). Further,
72% of patients with PIK3CA mutations also had a KRAS mutation
while only 46% of patients with wild-type PIK3CA had a KRAS
mutation (p = 0.03). PIK3CA mutations were significantly associ-
ated with KRAS mutations in both univariate and multivariate
models.
The median OS from time of diagnosis for patients with KRAS
mutations was shorter than for those with wild-type KRAS (57.5 vs
89.5 months; p = 0.007) (Figure 1). Furthermore, in multivariate
analysis, Duke’s stage at diagnosis and KRAS status were significant
independent predictors of survival. BRAF mutations have recently
been found to be prognostic for shorter OS in patients with
mCRC. [10,11] However, the role of KRAS status as a predictor of
OS is controversial. A previous retrospective study including 3,439
patients in a multivariate survival analysis found that only p.G12V
mutations were predictive of poor survival. Interestingly, the
incidence of p.G12V mutations in that study was considerably
lower than the one reported in the COSMIC database (8% vs.
23%). A recent study showed increased OS in patients with KRAS
wild-type mCRC treated with best supportive care compared to
patients with KRAS-mutant mCRC. [1] However, after progres-
sing on supportive care, patients with KRAS wild-type were
allowed to cross over to panitumumab; therefore, treatment effect
cannot be completely ruled out. It is unclear why different studies
show conflicting data regarding the prognostic effect of KRAS,
though it is conceivable that this is related to therapy given and/or
other selection factors.
In univariate analysis, patients with PIK3CA mutations more
frequently had mucinous tumors (p = 0.04), and tended to less
frequently have liver metastases compared to patients with PIK3CA
wild-type tumors. Only the association with mucinous tumor was
(marginally) significant in the multivariate analysis (p = 0.05).
PIK3CA status was not an independent variable predicting survival
in multivariate analysis. At the molecular level, 72% of patients
with PIK3CA mutations had coexisting KRAS mutations. Of
possible interest, patients with mutated PIK3CA had a trend to
a shorter PFS when treated with anti-EGFR therapies than those
with wild-type PIK3CA (median= 22 weeks vs. 17 weeks, p = 0.07).
Other reports also suggest that patients with PIK3CAmutations are
less sensitive to anti-EGFR therapies. [4] However, a larger
multicenter analysis recently found that only PIK3CA mutations in
exon 20 were associated with a worse outcome after treatment
with cetuximab. [6] Although several lines of evidence indicate
that patients with colorectal cancer and KRAS mutations do poorly
with EGFR inhibitors, recent data suggests that those individuals
with KRAS mutation p.G13D may benefit from EGFR inhibitors.
[3] We, therefore, analyzed patients with p.G13D KRAS mutations
for exon 20 PIK3CA mutations and found none, whereas these
Figure 2. Waterfall plot with the responses by RECIST in the 78 assessable patients with mCRC that were treated with PI3K/AKT/
mTOR inhibitors.
doi:10.1371/journal.pone.0038033.g002
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mutations were found in other KRAS mutant subtypes. However,
the small number of patients assessed precludes definitive
conclusions. It may be warranted to evaluate, in prospective
studies, whether or not co-existence of exon 20 mutated PIK3CA in
certain subtypes of KRAS mutant disease could contribute to
EGFR inhibitor resistance.
Eighty patients were treated on protocols containing PI3K/
AKT/mTOR inhibitors of whom 78 (98%) were assessable. 23%
achieved SD $6 months/CR/PR. There was no significant
difference in the rate of SD $6 months/CR/PR between those
with wild-type or mutant KRAS. Of interest, only 1 patient with
a PIK3CA mutation achieved SD $6 months/CR/PR when
treated with a PI3K/Akt/mTOR inhibitor. Most of these patients
(67%) had co-existing KRAS mutations, which may explain their
resistance. Indeed, activation of the MAPK pathway has recently
been proposed as a mechanism of resistance to PI3K inhibitors.
[12] Even so, it may be of interest that among the 13 patients that
had some kind of tumor reduction, 7 had KRAS mutation. The
latter suggests that though the rates of SD $6 months/CR/PR
were low, and patients with co-existing KRAS and PIK3CA
mutations did not respond, the presence of a KRAS mutation
alone is not an absolute indicator of complete resistance to PI3K/
Akt/mTOR inhibitor-based therapy. We recently reported that
coexistence of PIK3CA and KRAS mutations was not predictive of
resistance to PI3K/Akt/mTOR in patients with ovarian cancer.
[13] Certainly, the disease-type context plays a role and additional
mutations not included in this analysis may impact the response to
these therapies. A recent work has shown that activation of
a complex network of feed-back loops may for instance explain
resistance to BRAF inhibitors in patients with colorectal cancer
with BRAF mutations. [14]
Unexpectedly, 27% of patients with wild-type or unknown
PIK3CA status treated with a PI3K/Akt/mTOR inhibitor attained
SD $6 months/CR/PR (p= 0.09). It is possible that a molecular
aberration in the PI3K/Akt/mTOR pathway existed in these
patients but was not recognized, and that such an aberration may
not have the same propensity to co-exist with KRAS or BRAF
mutations. Indeed, loss of PTEN expression, which often indicates
a PTEN mutation, has been reported in 40% of patients with
metastatic colorectal cancer. [15]
A total of 10 patients (nine of whom had KRAS or BRAF
mutations and none of whom had PIK3CA mutations) were treated
with MAPK pathway inhibitors (generally BRAF or MEK
inhibitors). Although the numbers of patients are small, none
achieved SD $6 months/CR/PR.
Our work has several limitations. First, this is a retrospective
study in a single institution with a relatively small number of
patients. Second, we could not validate response rate to anti-
EGFR therapies as this information was not available for many of
the patients who were treated in institutions other than MD
Anderson prior to being referred to our unit; hence, the only
available clinical outcome for these patients was PFS. Third, all
mutational analyses could not be completed for all patients
included in the study because of limited amounts of available
tissue.
In conclusion, we show that KRAS and PIK3CA mutations are
frequently associated in patients with colorectal cancer. In the
context of early clinical trials, drugs targeting the PI3K/Akt/
mTOR pathway had limited activity in these patients, even in the
presence of PIK3CA mutations, possibly because of the frequent
coexistence of activating mutations in the MAPK pathway.
Methods
Patients
We retrospectively reviewed the clinicopathologic characteris-
tics and clinical outcomes of 238 consecutive patients with mCRC
who were seen in the Phase 1 Clinic (Clinical Center for Targeted
Therapy) at The University of Texas MD Anderson Cancer
Center beginning in October 2008, and for whom KRAS status was
known. Data were collected from transcribed notes and radiology
reports in the electronic database of these patients. The sites of
metastatic disease were collected from the last available radiology
report for each patient. Pathology was reviewed by an MD
Anderson pathologist in all cases. The MD Anderson Cancer
Center Institutional Review Board has approved the study.
Written consent was given by the patients for their information
to be stored in the hospital database and used for research.
KRAS, BRAF, PIK3CA Mutation Testing
Mutation testing was done in the Clinical Laboratory Improve-
ment Amendment-certified Molecular Diagnostic Laboratory
within the Division of Pathology and Laboratory Medicine at
MD Anderson. DNA was extracted from micro-dissected paraffin-
embedded tumor and analyzed by a polymerase chain reaction
(PCR)-based DNA sequencing method to examine codons 12, 13
and 61 of the KRAS proto-oncogene. The sensitivity of detection of
this assay is approximately 1 in 10 mutation-bearing cells in the
microdissected area. Whenever possible, analysis was done for
PIK3CA mutations in codons [c] 532–554 of exon 9 (helical
domain) and c1011–1062 of exon 20 (kinase domain) and BRAF
c595–600 mutations of exon 15 by pyrosequencing as previously
described. [16]
Statistical Methods
Statistical analysis was performed and validated by our
statistician (XW). Patient characteristics are summarized using
descriptive statistics. The association between KRAS or PIK3CA
mutation status and patient characteristics was assessed using
Fisher’s exact test. Overall survival (OS) is defined as the time
interval between date of diagnosis and death. Patients who were
alive were censored at the last follow-up date. Progression-free
survival (PFS) was defined as the time from treatment initiation to
detection of progressive disease or death. Patients who did not
progress while on treatment were censored at the last date of
follow up. The probabilities of OS and PFS were estimated using
the method of Kaplan and Meier and were compared among
subgroups of patients using the log-rank test. [17,18] Cox
proportional hazards regression models were fit to assess the
association between OS and patient characteristics and KRAS
mutation status. [19] Univariate and multiple logistic regression
models were fit to assess the association between KRAS and
PIK3CA mutation and patient clinical characteristics. Initially,
univariate logistic regression models were fit and variables with p-
values less than 0.5 were included in the multiple logistic
regression model. We then performed backward model selection
and kept only those variables with p-values less than 0.05. All
statistical analyses were conducted using SAS software (version9.2)
and Splus (version 8.0).
Supporting Information
Figure S1 Kaplan-Meier plot of progression-free sur-
vival (PFS) and PIK3CA status on patients with mCRC
treated with regimens including anti-EGFR therapies.
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Patients with mCRC/PIK3CAmutant had a trend toward a shorter
PFS compared to PIK3CA wild-type patients.
(TIF)
Table S1 Median overall survival (OS) for each group of
KRAS mutations.
(DOCX)
Table S2 Type of PIK3CA mutations found in patients
with KRAS mutations*.
(DOCX)
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